Synthetic Biology: Global Markets
The global synthetic biology market reached nearly $2.1 billion in 2012 and $2.7 billion in 2013. This market is expected to grow to $11.8 billion in 2018 with a compound annual growth rate (CAGR) of 34.4% over the five-year period from 2013 to 2018.
- An overview of the global market for synthetic biology.
- Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Information on the applications for synthetic biology including specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.
- An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
- Comprehensive profiles of leading companies in the industry.
The study scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercialized or are forecast to be commercialized within the next five years.
in this Report
|Technologies not Specifically
Covered in this Report
|Synthetic biology||Systems biology|
|DNA synthesis||Genetic engineering|
Source: BCC Research
We analyze key synthetic biology technologies and products to determine present and future market status, and forecasted growth from 2013 through 2018. We also discuss strategic alliances, industry structures, competitive dynamics, patents, and market driving forces.
BCC Research examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceuticals, biofuels, and specialty chemicals. The role of key strategic alliances from 2012 through 2014 is discussed. Emerging markets including synthetic genes, synthetic biology–enabled drugs and vaccines, chassis organisms, as well as metabolically–engineered factories for producing synthetic fuels and specialty chemicals are analyzed and more than 130 companies in these fields are highlighted.
John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.
Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.
- Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets (BIO150D)
- DNA Data Storage: Global Markets and Technologies (BIO202A)
- Direct-to-Consumer Genetic Testing: Global Markets and Technologies (MDS008A)
- Next Generation Cancer Diagnostics: Technologies and Global Markets (BIO081C)
- Rare Disease Diagnostics: Technologies and Global Markets (PHM227A)
The global value of the synthetic biology market reached $1.1 billion in 2010. It is expected to reach $1.6 billion in 2011 and it will further grow to $10.8 billion by 2016, increasing at a compound annual growth rate (CAGR) of 45.8.%.
- The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%.
- The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%.
- The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013.